2020年系统性红斑狼疮研究新进展

doi:10.35541/cjd.20210037

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (6): 542-545.doi: 10.35541/cjd.20210037

2020年系统性红斑狼疮研究新进展

罗帅寒天¹ 龙海¹ 陆前进^1，2

¹中南大学湘雅二医院皮肤科，长沙 410011；²中国医学科学院、北京协和医学院皮肤病医院，南京 210042

收稿日期:2021-01-14 修回日期:2021-02-21 发布日期:2021-05-31
通讯作者: 陆前进 E-mail:qianlu5860@gmail.com
基金资助:
国家自然科学基金（81703133、81773334）；湖南省科技创新计划项目（2018RS3031）；长沙市科技计划项目（KQ1802002）

Research advances in systemic lupus erythematosus in 2020

Luo Shuaihantian¹, Long Hai¹, Lu Qianjin^1,2

¹Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha 410011, China; ²Department of Dermatology, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2021-01-14 Revised:2021-02-21 Published:2021-05-31
Contact: Lu Qianjin E-mail:qianlu5860@gmail.com
Supported by:
National Natural Science Foundation of China （81703133, 81773334）; Hunan Science and Technology Innovation Project （2018RS3031）; Changsha Science and Technology Planning Project （KQ1802002）

摘要/Abstract

摘要： 【摘要】系统性红斑狼疮病因尚不清楚，发病机制复杂。2020年，国内外研究者在其发病机制、诊断和评估、治疗方面取得了一系列新进展，本文综述主要代表性成果。

关键词: 红斑狼疮, 系统性, 诊断, 治疗, 生物制剂, 生物标志物, 研究进展

Abstract: 【Abstract】 The etiology of systemic lupus erythematosus is still unclear, and its pathogenesis is complicated. In 2020, Chinese and international researchers made a lot of new progress in the pathogenesis, diagnosis and evaluation, and treatment of systemic lupus erythematosus. This review summarizes major representative advances.

Key words: Lupus erythematosus, systemic, Diagnosis, Therapy, Biological agents, Biomarker, Research advance

罗帅寒天龙海陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021,54(6):542-545. doi:10.35541/cjd.20210037

Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2020[J]. Chinese Journal of Dermatology, 2021, 54(6): 542-545.doi:10.35541/cjd.20210037

参考文献 28

［1］	罗帅寒天, 龙海, 陆前进. 2018年系统性红斑狼疮研究新进展［J］. 中华皮肤科杂志, 2020,53（8）:665⁃667. doi: 10.35541/cjd. 20190298.
［2］	陆前进, 罗帅寒天. 系统性红斑狼疮的诊疗进展［J］. 中华皮肤科杂志, 2018,51（1）:1⁃4. doi: 10.3760/cma.j.issn.0412⁃4030. 2018.01.001.
［3］	Kazimierczyk M, Kasprowicz MK, Kasprzyk ME, et al. Human long noncoding RNAinteractome: detection, characterization and function［J］. Int J MolSci, 2020,21（3）:1027. doi: 10.3390/ijms21031027.
［4］	Moore JB 4th, Uchida S. Functional characterization of long noncoding RNAs［J］. CurrOpinCardiol, 2020,35（3）:199⁃206. doi: 10.1097/HCO.0000000000000725.
［5］	Fan Z, Chen X, Liu L, et al. Association of the polymorphism rs13259960 in SLEAR with predisposition to systemic lupus erythematosus［J］. Arthritis Rheumatol, 2020,72（6）:985⁃996. doi: 10.1002/art.41200.
［6］	Löfgren SE, Frostegård J, Truedsson L, et al. Genetic association of miRNA⁃146a with systemic lupus erythematosus in Europeans through decreased expression of the gene［J］. Genes Immun, 2012,13（3）:268⁃274. doi: 10.1038/gene.2011.84.
［7］	Hou G, Harley I, Lu X, et al. SLE non⁃coding genetic risk variant determines the epigenetic dysfunction of an immune cell specific enhancer that controls disease⁃critical microRNA expression［J］. Nat Commun, 2021,12（1）:135. doi: 10.1038/s41467⁃020⁃20460⁃1.
［8］	Kuo CF, Grainge MJ, Valdes AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families［J］. JAMA Intern Med, 2015,175（9）:1518⁃1526. doi: 10.1001/jamainternmed.2015.3528.
［9］	Wang YF, Zhang Y, Lin Z, et al. Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups［J］. Nat Commun, 2021,12（1）:772. doi: 10.1038/s41467⁃021⁃21049⁃y.
［10］	Lee JY, Park JK, Lee EY, et al. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response［J］. Arthritis Res Ther, 2016,18（1）:264. doi: 10.1186/s13075⁃016⁃1159⁃y.
［11］	张淑娟, 唐亚萍, 梁景耀, 等. 姜黄素逆转系统性红斑狼疮患者外泌体诱导的巨噬细胞吞噬功能受损［J］. 中华皮肤科杂志, 2019,52（6）:378⁃382. doi: 10.3760/cma.j.issn.0412⁃4030. 2019.06.002.
［12］	Tsokos GC, Lo MS, Costa Reis P, et al. New insights into the immunopathogenesis of systemic lupus erythematosus［J］. Nat Rev Rheumatol, 2016,12（12）:716⁃730. doi: 10.1038/nrrheum. 2016.186.
［13］	Lee WS, Amengual O. B cells targeting therapy in the management of systemic lupus erythematosus［J］. Immunol Med, 2020,43（1）:16⁃35. doi: 10.1080/25785826.2019.1698929.
［14］	Salazar⁃Camarena DC, Palafox⁃Sánchez CA, Cruz A, et al. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients［J］. Sci Rep, 2020,10（1）:6236. doi: 10.1038/s41598⁃020⁃63390⁃0.
［15］	Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163（+） macrophages in inflammatory and malignant diseases［J］. Int J MolSci, 2020,21（15）:5497. doi: 10.3390/ijms21155497.
［16］	Li J, Yu YF, Liu CH, et al. Significance of M2 macrophages in glomerulonephritis with crescents［J］. Pathol Res Pract, 2017,213（9）:1215⁃1220. doi: 10.1016/j.prp.2017.04.011.
［17］	Li J, Liu CH, Xu DL, et al. Significance of CD163⁃Positive macrophages in proliferative glomerulonephritis［J］. Am J Med Sci, 2015,350（5）:387⁃392. doi: 10.1097/MAJ.0000000000000569.
［18］	Mejia⁃Vilet JM, Zhang XL, Cruz C, et al. Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis［J］. J Am Soc Nephrol, 2020,31（6）:1335⁃1347. doi: 10.1681/ASN. 2019121285.
［19］	You L, Wu W, Wang X, et al. The role of hypoxia⁃inducible factor 1 in tumor immune evasion［J］. Med Res Rev, 2021, 41（3）:1622⁃1643. doi: 10.1002/med.21771.
［20］	Deng W, Ren Y, Feng X, et al. Hypoxia inducible factor⁃1 alpha promotes mesangial cell proliferation in lupus nephritis［J］. Am J Nephrol, 2014,40（6）:507⁃515. doi: 10.1159/000369564.
［21］	Ma Z, Xiang X, Li S, et al. Targeting hypoxia⁃inducible factor⁃1, for cancer treatment: recent advances in developing small⁃molecule inhibitors from natural compounds［J］. Semin Cancer Biol, 2020［2020⁃09⁃30］. doi: 10.1016/j.semcancer.2020.09.011.
［22］	Chen PM, Wilson PC, Shyer JA, et al. Kidney tissue hypoxia dictates T cell⁃mediated injury in murine lupus nephritis［J］. Sci Transl Med, 2020,12（538）:eaay1620. doi: 10.1126/scitranslmed.aay1620.
［23］	Hogan KA, Chini C, Chini EN. The multi⁃faceted ecto⁃enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases［J］. Front Immunol, 2019,10:1187. doi: 10.3389/fimmu. 2019.01187.
［24］	Ostendorf L, Burns M, Durek P, et al. Targeting CD38 withdaratumumab in refractory systemic lupus erythematosus［J］. N Engl J Med, 2020,383（12）:1149⁃1155. doi: 10.1056/NEJMoa2023325.
［25］	国家食品药品监督管理局. 2020年12月07日药品批准证明文件待领取信息发布［EB/OL］. （2020⁃12⁃07）［2020⁃12⁃08］. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20201207163 143123.html.
［26］	Dimelow R, Ji B, Struemper H. Pharmacokinetics of belimumab in children with systemic lupus erythematosus［J］. Clin Pharmacol Drug Dev, 2020［2020⁃11⁃30］. doi: 10.1002/cpdd.889.
［27］	Collins CE, Cortes⁃Hernández J, Garcia MA, et al. Real⁃world effectiveness of belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi⁃country data from the OBSErve studies ［J］. RheumatolTher, 2020,7（4）:949⁃965. doi: 10.1007/s40744⁃020⁃00243⁃2.
［28］	Bell CF, Priest J, Stott⁃Miller M, et al. Real⁃world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA［J］. Lupus Sci Med, 2020,7（1）:e000357. doi: 10.1136/lupus⁃2019⁃000357.

[1]	张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767.
[2]	李妍李明徐薇李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263.
[3]	李浩, 王俐韩宪伟孙彤苏芳孙晓冬韩莹杨国玲刘晓明王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218.
[4]	王晓雯李若瑜. 白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略[J]. 中华皮肤科杂志, 2022, 55(3): 272-275.
[5]	吕玲吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279.
[6]	李锁向睿宇李志量荆可王媛张寒梅冯素英. 盐裂皮肤间接免疫荧光技术在大疱性类天疱疮诊断中的价值评估[J]. 中华皮肤科杂志, 2022, 55(3): 235-237.
[7]	《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
[8]	王娟娟陈容季江苏文星魏钰倩赵莹尹兴平苏玉华施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234.
[9]	张婷婷朱凤仪杨梅张平夏萍周小勇. 司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210644-e20210644.
[10]	温广东冒丹丹张原媛窦沅青赵培吴晨雨张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 0(2): 20210694-e20210694.
[11]	欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184.
[12]	包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156.
[13]	李赛, 薛华忠, 张树文, 蒋娟, 齐淑贞, 赵园园, 张津萍, 沙仲, 乐文静, 王碧伟, 赵诗轩, 朱小凤, 苏晓红. 多西环素-莫西沙星序贯疗法治疗生殖支原体尿道炎/宫颈炎的临床观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210631-e20210631.
[14]	焦晓燕, 尹光文, 阴亚坤, 李冬芹. 妊娠期、围生期带状疱疹25例临床分析[J]. 中华皮肤科杂志, 2022, 0(2): 20210384-e20210384.
[15]	王佳绮, 王平, 李刘雨, 樊奇敏, 朱蒙燕, 王燕清, 周鸿宇, 沈宏, 许爱娥. 皮肤色素减退性淋巴增殖性疾病41例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(2): 110-115.

2020年系统性红斑狼疮研究新进展

Research advances in systemic lupus erythematosus in 2020

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

Metrics

本文评价

推荐阅读 10